NO20061541L - Behandling av gastroparese og ikke-ulceros dyspepsi med GABAB-agonister - Google Patents

Behandling av gastroparese og ikke-ulceros dyspepsi med GABAB-agonister

Info

Publication number
NO20061541L
NO20061541L NO20061541A NO20061541A NO20061541L NO 20061541 L NO20061541 L NO 20061541L NO 20061541 A NO20061541 A NO 20061541A NO 20061541 A NO20061541 A NO 20061541A NO 20061541 L NO20061541 L NO 20061541L
Authority
NO
Norway
Prior art keywords
gastroparesis
treatment
baclofen
methods
formulations
Prior art date
Application number
NO20061541A
Other languages
English (en)
Inventor
John G Devane
Jackie Butler
Original Assignee
Agi Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agi Therapeutics Ltd filed Critical Agi Therapeutics Ltd
Publication of NO20061541L publication Critical patent/NO20061541L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelsen angår formuleringer som omfatter en terapeutisk effektiv mengde av baklofen eller (R)-baklofen eller et av dets farmasøytisk akseptable salter og fremgangsmåter for deres anvendelse. De foreliggende formuleringer og fremgangsmåter er utformet for å frigjøre en terapeutisk mengde av baklofen på en måte som maksimerer deres terapeutiske effekt. Fremgangsmåtene og formuleringene er spesielt godt egnet for behandling av gastroparese og ikke-ulcerøs dyspepsi.
NO20061541A 2003-09-12 2006-04-05 Behandling av gastroparese og ikke-ulceros dyspepsi med GABAB-agonister NO20061541L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50224203P 2003-09-12 2003-09-12
US55394004P 2004-03-18 2004-03-18
PCT/IB2004/003299 WO2005025559A1 (en) 2003-09-12 2004-09-10 Treatment of gastroparesis and nonulcer dyspepsia with gabab agonists

Publications (1)

Publication Number Publication Date
NO20061541L true NO20061541L (no) 2006-04-05

Family

ID=34316518

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061541A NO20061541L (no) 2003-09-12 2006-04-05 Behandling av gastroparese og ikke-ulceros dyspepsi med GABAB-agonister

Country Status (9)

Country Link
US (2) US20050090554A1 (no)
EP (1) EP1675581A1 (no)
JP (1) JP2007505099A (no)
AU (1) AU2004271805A1 (no)
CA (1) CA2537343A1 (no)
IL (1) IL173930A0 (no)
MX (1) MXPA06002572A (no)
NO (1) NO20061541L (no)
WO (1) WO2005025559A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7824697B2 (en) 2004-07-12 2010-11-02 Board Of Regents, The University Of Texas System High concentration baclofen preparations
AU2007201808B8 (en) * 2006-04-26 2013-09-05 Sun Pharmaceutical Advanced Research Company Ltd A method for alleviating signs and symptoms of spasticity
WO2008011016A2 (en) * 2006-07-18 2008-01-24 Dynogen Pharmaceuticals, Inc. Treating gastroesophageal reflux disease with 5-ht3- and gaba receptor agonists
WO2008018275A1 (fr) * 2006-08-11 2008-02-14 National University Corporation Nagoya University Agent anti-obésité et son utilisation
PT2083811T (pt) * 2006-11-22 2017-01-23 Clinical Res Ass Llc Métodos de tratamento da síndrome de down, síndrome do x frágil e autismo
US8969414B2 (en) * 2009-02-06 2015-03-03 Mallinckrodt Llc Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products
US20150258279A1 (en) 2008-03-18 2015-09-17 Mallinckrodt Llc Intrathecal baclofen pharmaceutical dosage forms and related delivery system
US9693981B2 (en) * 2008-12-04 2017-07-04 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
WO2010104175A1 (ja) * 2009-03-13 2010-09-16 味の素株式会社 経口用組成物
US9498440B2 (en) * 2009-05-22 2016-11-22 Inventia Healthcare Private Limited Extended release pharmaceutical compositions
EP2633884A1 (en) * 2010-01-07 2013-09-04 Akron Molecules GmbH Obesity small molecules
KR101351181B1 (ko) 2010-05-11 2014-01-14 가천대학교 산학협력단 단핵식세포계 세포 내에서 ａｇｅ-알부민의 합성 저해 또는 분비 저해에 의한 세포사 유도 저해 방법
US8628947B2 (en) 2010-08-30 2014-01-14 Intervet Inc. Potomac horse fever isolates
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
ES2564489T3 (es) 2011-03-23 2016-03-23 Raqualia Pharma Inc. Un agonista del receptor de 5-HT4 como agente procinético
FR2991879B1 (fr) * 2012-06-14 2014-11-21 Ethypharm Sa Formulation pharmaceutique orale de molecules bcs de classe iii
FR3014692B1 (fr) * 2013-12-18 2016-01-29 Ethypharm Sa Compositions pharmaceutiques orales a retention gastrique.
KR102526521B1 (ko) * 2014-05-16 2023-04-27 라퀄리아 파마 인코포레이티드 위부전마비용 5-ht4 수용체 작용제
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
WO2016132220A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release oral dosage form of gaba receptor agonist
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
US10588863B2 (en) * 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
US10987311B2 (en) * 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
DK3824881T3 (da) * 2018-06-18 2022-05-09 Amneal Complex Products Res Llc Sammensætning omfattende pyridostigminbromid med forlænget frigivelse
US20220016061A1 (en) * 2018-10-04 2022-01-20 Medrx Co., Ltd. Preparation Stabilized by Means of Nonaqueous Solvent
WO2023055457A1 (en) * 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Baclofen-containing granule formulations and reduced patient exposure to metabolite variations
US11491125B1 (en) 2021-09-29 2022-11-08 Amneal Pharmaceuticals Llc Baclofen formulations and methods of minimizing patient exposure to metabolite variations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9308430D0 (en) * 1993-04-23 1993-06-09 Glaxo Group Ltd Medicaments
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
US6051734A (en) * 1995-12-20 2000-04-18 Farmarc Nederland B.V. Process for the optical resolution of 3-(p-chlorophenyl)-glutaramide
TWI263496B (en) * 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
WO2003026631A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
EP1503744A1 (en) * 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
US7109239B2 (en) * 2003-08-20 2006-09-19 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use

Also Published As

Publication number Publication date
EP1675581A1 (en) 2006-07-05
US20050090554A1 (en) 2005-04-28
US20090246233A1 (en) 2009-10-01
MXPA06002572A (es) 2006-06-05
JP2007505099A (ja) 2007-03-08
IL173930A0 (en) 2006-07-05
CA2537343A1 (en) 2005-03-24
AU2004271805A1 (en) 2005-03-24
WO2005025559A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
NO20061541L (no) Behandling av gastroparese og ikke-ulceros dyspepsi med GABAB-agonister
NO20054546L (no) Kinazoliner anvendelige som modulatorer av ionekanaler
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
NO20054371L (no) Somatostatin-dopamin kimaere analoger
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
HK1125039A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
NO20054848L (no) Substituerte p-diaminobenzenderivater
NO20012158L (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
NO20051726L (no) Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
HK1124546A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
DK2040703T3 (da) Derivater af 2-benzoylimidazopyridiner, fremstilling deraf og terapeutisk anvendelse deraf
NO20065835L (no) Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander
DE60306546D1 (de) Entzündungshemmende 3-arylthio-3-thiazolylalkylamine
ATE344262T1 (de) 2-heteroarylcarbonsäureamide

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application